More than 300 million people worldwide are living with chronic hepatitis B or C infection, making viral hepatitis many times more common than HIV.¹ Gilead has:

• Provided medicines that can cure chronic hepatitis C virus (HCV) infection²
• Helped manage chronic hepatitis B virus (HBV) infection²

Beyond therapeutic advancement, Gilead has:

• Expanded hepatitis screening for at-risk individuals and increased access to our medicines around the world¹
• Actively supported the efforts of governments and partnered with the World Health Organization (WHO) with the goal of eliminating viral hepatitis globally by 2030¹

Through our antiretroviral therapies, we’ve helped transform HIV infection into a chronic, manageable condition for many.¹

Since the early days of the HIV epidemic, antiretroviral therapy has evolved from complex regimens involving a large number of daily pills to simplified combination regimens.^2,3 Gilead’s innovations include multiple once-daily, complete single-tablet regimens for people living with HIV.

We’re at the forefront of pre-exposure prophylaxis (PrEP), an approach that involves the use of antiretroviral medication, including once-daily single-tablet regimens, to reduce the chances of sexually acquiring HIV-1 infection in individuals who are HIV-negative and at risk.

Kite, a Gilead company, is pioneering CAR T-cell therapy to help treat patients with certain hematologic cancers.

This innovative approach re-engineers a patient’s white blood cells to transform their immune system into their own cancer-fighting therapy.